It is important to inform clinicians about this new section of the NCCN Guidelines for Neuroendocrine and Adrenal Tumors, which include recommendations for the evaluation, management, and surveillance of well-differentiated G3 NETs. Keeping clinicians abreast of updated treatment options may help improve clinical decision-making to better address patients’ medical needs.

Clinical trials are continuing to investigate the role of induction chemotherapy prior to systemic therapy/radiation therapy for patients with locoregionally advanced nasopharyngeal carcinoma. New evidence regarding the addition of a PD-1 inhibitor to gemcitabine/cisplatin provides an emerging avenue of treatment for patients with recurrent or metastatic disease. It is important for clinicians to remain current on emerging treatment options for patients with nasopharyngeal carcinoma.

Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.

In order to optimize overall patient outcomes, clinicians need to understand the evidence behind the current guidelines’ recommendations, the rationale for appropriate treatment selection, and the management of any treatment- or multiple myeloma-specific adverse events.